Company intelligence / Profile preview

Von Rose

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Vonros is an early-stage biotechnology company focused on developing novel therapeutics for cardiovascular and metabolic diseases. Founded by a team of experienced industry veterans from companies such as MyoKardia and BridgeBio, the company aims to address significant unmet needs in heart health through precision medicine approaches. Vonros operates primarily in stealth mode but has successfully secured significant venture capital funding to advance its internal pipeline. The company's strategy involves leveraging deep biological insights to target specific pathways involved in disease progression.

Therapeutic areas: CardiovascularMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Von Rose.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Von Rose.

Explore the full profile